PMID- 12531812
OWN - NLM
STAT- MEDLINE
DCOM- 20030718
LR  - 20220318
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 101
IP  - 10
DP  - 2003 May 15
TI  - Utility of FDG-PET scanning in lymphoma by WHO classification.
PG  - 3875-6
AB  - We retrospectively evaluated (18)fluoro-2-deoxyglucose positron emission 
      tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results 
      with pathologic diagnosis using the World Health Organization (WHO) 
      classification system. In total, FDG-PET detected disease in at least one site in 
      161 patients (94%) and failed to detect disease in 11 patients (6%). The most 
      frequent lymphoma diagnoses were diffuse large B-cell lymphoma (LBCL; n = 51), 
      Hodgkin lymphoma (HL; n = 47), follicular lymphoma (FL; n = 42), marginal zone 
      lymphoma (MZL; n = 12), mantle cell lymphoma (MCL; n = 7), and peripheral T-cell 
      lymphoma (PTCL; n = 5). FDG-PET detected disease in 100% of patients with LBCL 
      and MCL and in 98% of patients with HL and FL. In contrast, FDG-PET detected 
      disease in only 67% of MZL and 40% of PTCL. Comparison with bone marrow biopsies 
      showed that FDG-PET was not reliable for detection of bone marrow involvement in 
      any lymphoma subtype.
FAU - Elstrom, Rebecca
AU  - Elstrom R
AD  - Abramson Family Cancer Research Institute of the University of Pennsylvania, 
      Philadelphia, USA. relstrom@mail.med.upenn.edu
FAU - Guan, Liang
AU  - Guan L
FAU - Baker, Gary
AU  - Baker G
FAU - Nakhoda, Khozaim
AU  - Nakhoda K
FAU - Vergilio, Jo-Anne
AU  - Vergilio JA
FAU - Zhuang, Hongming
AU  - Zhuang H
FAU - Pitsilos, Stephanie
AU  - Pitsilos S
FAU - Bagg, Adam
AU  - Bagg A
FAU - Downs, Lisa
AU  - Downs L
FAU - Mehrotra, Amit
AU  - Mehrotra A
FAU - Kim, Scott
AU  - Kim S
FAU - Alavi, Abass
AU  - Alavi A
FAU - Schuster, Stephen J
AU  - Schuster SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20030116
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/classification/*diagnostic imaging
MH  - Radiopharmaceuticals/therapeutic use
MH  - Recurrence
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - *Tomography, Emission-Computed
EDAT- 2003/01/18 04:00
MHDA- 2003/07/19 05:00
CRDT- 2003/01/18 04:00
PHST- 2003/01/18 04:00 [pubmed]
PHST- 2003/07/19 05:00 [medline]
PHST- 2003/01/18 04:00 [entrez]
AID - S0006-4971(20)44433-7 [pii]
AID - 10.1182/blood-2002-09-2778 [doi]
PST - ppublish
SO  - Blood. 2003 May 15;101(10):3875-6. doi: 10.1182/blood-2002-09-2778. Epub 2003 Jan 
      16.